Suboptimal maternal diets alter mu opioid receptor and dopamine type 1 receptor binding but exert no effect on dopamine transporters in the offspring brain.
Birthweight is a marker for suboptimal fetal growth and development in utero. Offspring can be born large for gestational age (LGA), which is linked to maternal obesity or excessive gestational weight gain, as well as small for gestational age (SGA), arising from nutrient or calorie deficiency, placental dysfunction, or other maternal conditions (hypertension, infection). In humans, LGA and SGA babies are at an increased risk for certain neurodevelopmental disorders, including Attention Deficit/Hyperactivity Disorder, schizophrenia, and social and mood disorders. Using mouse models of LGA (maternal high fat (HF) diet) and SGA (maternal low protein (LP) diet) offspring, our lab has previously shown that these offspring display alterations in the expression of mesocorticolimbic genes that regulate dopamine and opioid function, thus indicating that these brain regions and neurotransmitter systems are vulnerable to gestational insults. Interestingly, these two maternal diets affected dopamine and opioid systems in somewhat opposing directions (e.g., LP offspring are generally hyperdopaminergic with reduced opioid expression, and the reverse is found for the HF offspring). These data largely involved evaluation at the transcriptional level, so the present experiment was designed to extend these analyses through an assessment of receptor binding. In this study, control, SGA and LGA offspring were generated from dams fed control, low protein or high fat diet, respectively, throughout pregnancy and lactation. At weaning, mice were placed on the control diet and sacrificed at 12 weeks of age. In vitro autoradiography was used to measure mu-opioid receptor (MOR), dopamine type 1 receptor (D1R), and dopamine transporter (DAT) binding level in mesolimbic brain regions. Results showed that the LP offspring (males and females) had significantly higher MOR and D1R binding than the control animals in the regions associated with reward. In HF offspring there were no differences in MOR binding, and limited increases in D1R binding, seen only in females in the nucleus accumbens core and the dorsomedial caudate/putamen. DAT binding revealed no differences in either models. In conclusion, LP but not HF offspring show significantly elevated MOR and D1R binding in the brain thus affecting DA and opioid signaling. These findings advance the current understanding of how suboptimal gestational diets can adversely impact neurodevelopment and increase the risk for disorders such as ADHD, obesity and addiction.
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA. Electronic address: pthanos@ria.buffalo.edu.
Panayotis K
PK
Thanos
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Jianmin
J
Zhuo
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Lisa
L
Robison
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Ronald
R
Kim
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Mala
M
Ananth
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Ilon
I
Choai
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Adam
A
Grunseich
Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati, Cincinnati, OH 45237, USA.
Nicola M
NM
Grissom
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Robert
R
George
Behavioral Neuropharmacology and Neuroimaging Laboratory, Research Institute on Addictions, University at Buffalo, 14203, USA.
Foteini
F
Delis
Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati, Cincinnati, OH 45237, USA.
Teresa M
TM
Reyes
D000818:Animals; D001921:Brain / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D005260:Female; D039382:Maternal Nutritional Physiological Phenomena; D051379:Mice; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D012201:Reward
D050483:Dopamine Plasma Membrane Transport Proteins; D017447:Receptors, Dopamine D1; D017450:Receptors, Opioid, mu
Dopamine; Maternal high fat diet; Maternal low protein diet; Opioid; Reward
PLoS One. 2013 May 02;8(5):e63549
23658839
Psychoneuroendocrinology. 2014 Nov;49:11-25
25038479
Trends Endocrinol Metab. 2010 Apr;21(4):206-13
20005734
BJOG. 2005 Oct;112(10):1431-3
16167951
Early Hum Dev. 1984 Sep;10(1-2):45-55
6499720
J Nutr. 2000 Oct;130(10):2582-9
11015493
Neuroscience. 2005;133(1):209-20
15893644
Neuropharmacology. 2002 Jun;42(8):1065-78
12128008
Mol Cell Proteomics. 2002 Apr;1(4):304-13
12096112
Neuroscience. 2000;99(2):267-77
10938432
Physiol Behav. 2005 Dec 15;86(5):773-95
16289609
J Neurosci. 2014 Mar 5;34(10):3706-18
24599469
Int J Dev Neurosci. 2013 Oct;31(6):406-14
23201144
Wiley Interdiscip Rev Syst Biol Med. 2010 Sep-Oct;2(5):577-593
20836049
Int J Gynaecol Obstet. 2005 Nov;91(2):125-31
16202415
Can J Psychiatry. 2012 Jul;57(7):422-8
22762297
Neuroscience. 1999;88(4):1093-135
10336124
Neuroscience. 1998 Mar;83(1):169-76
9466407
Am J Obstet Gynecol. 2012 Apr;206(4):314.e1-9
22464070
Am J Obstet Gynecol. 2007 Apr;196(4):322.e1-8
17403405
Lancet Glob Health. 2013 Jul;1(1):e26-36
25103583
Psychopharmacology (Berl). 2008 Mar;197(1):83-94
18004547
Schizophr Bull. 2009 May;35(3):568-76
19155344
Lancet. 1986 May 10;1(8489):1077-81
2871345
Neuroscience. 2011 Mar 10;176:225-36
21187125
Clin Sci (Lond). 1998 Aug;95(2):115-28
9680492
Neuropsychopharmacology. 2011 May;36(6):1199-206
21326195
Neuropharmacology. 2005 Mar;48(4):538-46
15755481
Obstet Gynecol Clin North Am. 2009 Jun;36(2):285-300, viii
19501314
FASEB J. 2013 Mar;27(3):1275-84
23233534
Endocrinology. 2010 Oct;151(10):4756-64
20685869
FEBS Lett. 2009 Dec 17;583(24):3966-73
19850042
J Pharmacol Exp Ther. 1998 May;285(2):908-14
9580643
Neuropsychopharmacology. 2014 Mar;39(4):801-10
23924601
Biol Psychiatry. 2010 Aug 15;68(4):314-9
20674602
J Addict Dis. 2004;23(3):39-53
15256343
Mol Pain. 2011 Jan 21;7:9
21255438
Neuroscience. 2017 Feb 7;342:200-211
26215917
Pharmacol Biochem Behav. 2007 Oct;87(4):426-33
17599397
Neuropsychopharmacology. 2015 May;40(6):1353-63
25418810
Mol Cell Biol. 1999 Mar;19(3):1720-30
10022859
Brain Res. 1997 Dec 5;778(1):73-88
9462879
Neuroscience. 2010 Jun 30;168(2):359-70
20394806
Science. 2010 Jul 30;329(5991):533-8
20671182
J Neurosci. 2011 Mar 2;31(9):3249-60
21368037
Brain Res. 2009 Apr 10;1265:196-204
19236855
Gene. 2007 Jun 15;395(1-2):98-107
17398041
J Pharmacol Exp Ther. 1999 Mar;288(3):1334-9
10027875